Tyra Biosciences to Host Conference Call on Initial Results of Oral Dabogratinib from the SURF302 Phase 2 Study for IR NMIBC on September 9, 2026

Data ReadoutDabogratinibNeutral

AI Analysis

Summary

Tyra Biosciences will host a conference call on September 9, 2026 to present initial results from the SURF302 Phase 2 study of oral dabogratinib for intermediate-risk non-muscle-invasive bladder cancer.

Clinical Trial Data

Phase

Phase 2

Outcome Details

Initial results from SURF302 Phase 2 study to be presented

Importance:6/10

Sentiment:

0.00

FGFR targeted therapyprecision medicinebladder canceroral therapy

Related Companies

$TYRA

Read the original article

Published by PR Newswire Pharma on September 4, 2026 12:00 PM

Read Original